Leap Therapeutics, Inc. (LPTX) financial statements (2022 and earlier)

Company profile

Business Address 47 THORNDIKE STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments114,91652,0713,89116,28425,737
Cash and cash equivalents114,91652,0713,89116,28425,737
Business combination, contingent consideration, asset1,18973185  
Other undisclosed current assets7691301651,0381,921
Total current assets:116,87452,2744,24117,32227,658
Noncurrent Assets
Operating lease, right-of-use asset459528 
Property, plant and equipment366512486135
Deposits noncurrent assets2939801,099  
Deferred income tax assets159179 
Other noncurrent assets90  1,5421,111
Deferred tax assets, net124158
Other undisclosed noncurrent assets 3451,984  
Total noncurrent assets:1,0372,0973,2071,7521,404
TOTAL ASSETS:117,91154,3717,44819,07429,062
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,5555,4648,0126,4516,083
Accounts payable4,1892,7174,5713,5792,622
Accrued liabilities5,3662,7473,4412,8723,461
Deferred revenue 1,500 
Debt 408   
Other undisclosed current liabilities432 474  
Total current liabilities:9,9877,3728,4866,4516,083
Noncurrent Liabilities
Long-term debt and lease obligation37144   
Operating lease, liability37144 
Liabilities, other than long-term debt 204159  
Financial instruments subject to mandatory redemption, settlement terms, share value, amount 204159  
Other undisclosed noncurrent liabilities(37) 5523,44811,862
Total noncurrent liabilities:373487113,44811,862
Total liabilities:10,0247,7209,1979,89917,945
Stockholders' equity
Stockholders' equity attributable to parent107,88746,651(1,749)9,17511,117
Common stock8860241512
Additional paid in capital371,638270,155193,319162,393141,770
Accumulated other comprehensive income (loss)(267)(579)76302(268)
Accumulated deficit(263,572)(222,985)(195,168)(153,535)(130,397)
Total stockholders' equity:107,88746,651(1,749)9,17511,117
TOTAL LIABILITIES AND EQUITY:117,91154,3717,44819,07429,062

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues1,5001,500   
Gross profit:1,5001,500   
Operating expenses(42,926)(30,039)(33,451)(30,751)(32,352)
Operating loss:(41,426)(28,539)(33,451)(30,751)(32,352)
Nonoperating income (expense)(379)738126(835)704
Foreign currency transaction gain (loss), before tax(379)738126(835)759
Interest and debt expense(41)(39)(23)(19)(121)
Loss from continuing operations before equity method investments, income taxes:(41,846)(27,840)(33,348)(31,605)(31,769)
Other undisclosed income from continuing operations before income taxes1,2353244458,4871,885
Loss from continuing operations before income taxes:(40,611)(27,516)(32,903)(23,118)(29,884)
Income tax expense (benefit)2423(20)157
Net loss attributable to parent:(40,587)(27,514)(32,900)(23,138)(29,727)
Preferred stock dividends and other adjustments (675)(359) (244)
Other undisclosed net loss available to common stockholders, basic (9,399)   
Net loss available to common stockholders, basic:(40,587)(37,588)(33,259)(23,138)(29,971)
Other undisclosed net loss available to common stockholders, diluted   (7,284)(473)
Net loss available to common stockholders, diluted:(40,587)(37,588)(33,259)(30,422)(30,444)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(40,587)(27,514)(32,900)(23,138)(29,727)
Comprehensive loss:(40,587)(27,514)(32,900)(23,138)(29,727)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent312(655)(226)570(562)
Comprehensive loss, net of tax, attributable to parent:(40,275)(28,169)(33,126)(22,568)(30,289)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: